Targeting redox sensitivity in melanoma treatment
Project 2: Targeting differentiation-linked redox sensitivity in melanoma
This study is looking at how melanoma cells can become tough to treat and is exploring a new way to make them more sensitive to therapies by understanding a special type of cell death, which could help improve treatment options for melanoma patients.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10878832 on NIH RePORTER |
What this research studies
This research investigates how melanoma cells can become resistant to current therapies, particularly through a process called dedifferentiation. By exploring a new type of cell death known as ferroptosis, the study aims to find ways to make these resistant cells more vulnerable to treatment. The approach involves using preclinical models to understand the interactions between iron metabolism and the mechanisms that protect melanoma cells from oxidative stress. This could lead to improved strategies for overcoming resistance in melanoma patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are melanoma patients who have experienced resistance to BRAF and MEK inhibitors or immunotherapies.
Not a fit: Patients with early-stage melanoma or those who have not yet undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide new treatment options for melanoma patients who have become resistant to existing therapies.
How similar studies have performed: Other research has shown promise in targeting cell death mechanisms in cancer, suggesting that this approach could be a valuable addition to melanoma treatment strategies.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Graeber, Thomas G — University of California Los Angeles
- Study coordinator: Graeber, Thomas G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.